Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/48291
Type
ArticleCopyright
Open access
Collections
- BA - IGM - Artigos de Periódicos [3332]
- INI - Artigos de Periódicos [3041]
Metadata
Show full item record
PRE-TREATMENT NEUTROPHIL COUNT AS A PREDICTOR OF ANTITUBERCULOSIS THERAPY OUTCOMES: A MULTICENTER PROSPECTIVE COHORT STUDY
Author
Carvalho, Anna Cristina C.
Amorim, Gustavo
Melo, Mayla G. M.
Silveira, Ana Karla A.
Vargas, Pedro H. L.
Moreira, Adriana S. R.
Rocha, Michael Santos
Souza, Alexandra B.
Arriaga Gutiérrez, María Belen
Pereira, Mariana Araújo
Figueiredo, Marina C.
Durovni, Betina
Silva, José R. Lapa e
Cavalcante, Solange
Rolla, Valeria C.
Sterling, Timothy R.
Santos, Marcelo Cordeiro
Andrade, Bruno de Bezerril
Silva, Elisangela C.
Kritski, Afrânio L.
RePORT Brazil consortium
Amorim, Gustavo
Melo, Mayla G. M.
Silveira, Ana Karla A.
Vargas, Pedro H. L.
Moreira, Adriana S. R.
Rocha, Michael Santos
Souza, Alexandra B.
Arriaga Gutiérrez, María Belen
Pereira, Mariana Araújo
Figueiredo, Marina C.
Durovni, Betina
Silva, José R. Lapa e
Cavalcante, Solange
Rolla, Valeria C.
Sterling, Timothy R.
Santos, Marcelo Cordeiro
Andrade, Bruno de Bezerril
Silva, Elisangela C.
Kritski, Afrânio L.
RePORT Brazil consortium
Affilliation
"Múltipla ver em Notas"
Abstract
Neutrophils have been associated with lung tissue damage in many
diseases, including tuberculosis (TB). Whether neutrophil count can serve as a
predictor of adverse treatment outcomes is unknown.
Methods: We prospectively assessed 936 patients (172 HIV-seropositive) with cultureconfirmed
pulmonary TB, enrolled in a multicenter prospective cohort study from different
regions in Brazil, from June 2015 to June 2019, and were followed up to two years. TB
patients had a baseline visit before treatment (month 0) and visits at month 2 and 6 (or at
the end of TB treatment). Smear microscopy, and culture for Mycobacterium tuberculosis
(MTB) were performed at TB diagnosis and during follow-up. Complete blood counts were
measured at baseline. Treatment outcome was defined as either unfavorable (death,
treatment failure or TB recurrence) or favorable (cure or treatment completion). We
performed multivariable logistic regression, with propensity score regression adjustment,
to estimate the association between neutrophil count with MTB culture result at month 2
and unfavorable treatment outcome. We used a propensity score adjustment instead of a
fully adjusted regression model due to the relatively low number of outcomes. Results: Among 682 patients who had MTB culture results at month 2, 40 (5.9%) had a
positive result. After regression with propensity score adjustment, no significant
association between baseline neutrophil count (103/mm3) and positive MTB culture at
month 2 was found among either HIV-seronegative (OR = 1.06, 95% CI = [0.95;1.19] or
HIV-seropositive patients (OR = 0.77, 95% CI = [0.51; 1.20]). Of 691 TB patients followed
up for at least 18 months and up to 24 months, 635 (91.9%) were either cured or
completed treatment, and 56 (8.1%) had an unfavorable treatment outcome. A
multivariable regression with propensity score adjustment found an association
between higher neutrophil count (103/mm3) at baseline and unfavorable outcome
among HIV-seronegative patients [OR= 1.17 (95% CI= [1.06;1.30]). In addition,
adjusted Cox regression found that higher baseline neutrophil count (103/mm3) was
associated with unfavorable treatment outcomes overall and among HIV-seronegative
patients (HR= 1.16 (95% CI = [1.05;1.27]).
Conclusion: Increased neutrophil count prior to anti-TB treatment initiation was
associated with unfavorable treatment outcomes, particularly among HIV-seronegative
patients. Further prospective studies evaluating neutrophil count in response to drug
treatment and association with TB treatment outcomes are warranted.
Share